DEF: Theriva Biologics Sets August 3rd Annual Meeting

Theriva Biologics, Inc. has announced its 2026 Annual Meeting of Stockholders to be held on August 3, 2026, to vote on key proposals including director elections, auditor ratification, stock incentive plan amendments, and share authorization.

Summary

• Theriva Biologics, Inc. will hold its 2026 Annual Meeting of Stockholders on August 3, 2026, at its principal place of business in Parets del Valls, Spain.
• The meeting agenda includes the election of four directors, ratification of BDO USA, P.C. as the independent auditor for 2026, and approval to amend the 2020 Stock Incentive Plan to increase the share pool to 6,500,000 shares.
• Stockholders will also vote on amending the Articles of Incorporation to increase authorized common stock to 450,000,000 shares and approving the issuance of up to 16,184,560 shares upon the exercise of warrants issued in a private placement on October 17, 2025.
• A proposal to adjourn the meeting if necessary to secure sufficient votes for the aforementioned proposals will also be presented.
• The record date for determining stockholders entitled to vote is June 23, 2026, with 45,892,668 shares of common stock outstanding as of that date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant potential dilution from warrant exercises and the past difficulties in obtaining stockholder approval for such matters, despite the strategic necessity of the proposals.

Positives

• The company is proactively seeking stockholder approval for key proposals aimed at supporting future growth and operations, including increasing the stock incentive plan and authorized share capital.
• The proposed increase in the stock incentive plan aims to attract, retain, and motivate employees, directors, and consultants through equity awards.
• The increase in authorized shares provides flexibility for future financing and strategic transactions.
• The company is seeking to ratify the appointment of BDO USA, P.C. as its independent auditor, indicating a commitment to financial transparency and compliance.

Negatives

• The potential issuance of up to 16,184,560 shares upon warrant exercise could lead to significant dilution for existing stockholders.
• The company has had to hold multiple special meetings previously to seek approval for warrant exercise, indicating prior difficulty in obtaining necessary stockholder support.
• The proposed increase in authorized shares, while providing flexibility, could be used to deter takeovers, potentially limiting opportunities for stockholders to sell shares at a premium.

Risks

• Failure to obtain stockholder approval for the plan increase, authorized share increase, or warrant exercise could hinder the company's ability to fund operations, attract talent, and pursue strategic opportunities.
• The issuance of shares upon warrant exercise could materially and adversely affect the market price of the company's common stock due to potential dilution.
• The company's ability to raise capital through equity financings or engage in acquisitions could be adversely affected if the authorized share count remains limited.
• The proposed increase in authorized shares could be used to oppose a hostile takeover attempt or delay changes in control or management, potentially limiting stockholder options.

Future Outlook

The company is seeking stockholder approval for proposals that will provide it with greater flexibility for future financing, strategic transactions, and employee incentives. The success of these proposals is crucial for the company's ability to execute its business plans and remain competitive.

Management Comments

• The Board believes that the proposed 2020 Plan Amendment is necessary for us to attract, retain and motivate our employees, directors and consultants through the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and other equity-based or equity-related awards.
• The Board of Directors believes that the Authorized Common Stock Increase is advisable and in our stockholders best interests. The Authorized Common Stock Increase will provide us with flexibility in completing financing and capital raising transactions as well as strategic transactions, which may be necessary for us to execute our future business plans.
• The Board is not seeking the approval of our stockholders to authorize our entry into or consummation of the Warrant Inducement, as the Warrant Inducement has already been completed. We are only asking for approval to issue up to an aggregate of 16,184,560 New Warrant Shares upon exercise of the New Warrants.

Industry Context

StockSavvy.ai notes that increasing authorized shares and stock incentive pools are common strategies for biotechnology companies, particularly those in earlier stages, to attract talent and fund operations and growth initiatives. However, the significant potential dilution from warrant exercises requires careful consideration by investors.

Comparison to Industry Standards

• The proposed increase in the 2020 Stock Incentive Plan to 6,500,000 shares is a significant increase from the current 4,500,000 shares, reflecting a common practice in the biotech sector to use equity as a key compensation tool.
• The proposed increase in authorized common stock to 450,000,000 shares from 350,000,000 shares is a substantial increase, providing ample room for future capital raises and strategic activities, which is typical for companies seeking to scale.
• The issuance of warrants with a reduced exercise price and a 200% coverage ratio upon exercise is a financing structure that has been observed in the market, particularly for companies needing to secure capital and incentivize investors, though it carries a high dilution risk.

Corporate Governance

Related Party Transactions

• MaryAnn Shallcross, wife of Steven Shallcross (CEO, CFO, Director), was employed as Director of Clinical Operations. Her compensation and equity awards for 2022, 2023, and 2024 are detailed. Her employment was terminated in September 2025, with separation terms including salary continuation, equity acceleration, and extended option exercise period.

Stakeholder Impact

• Shareholders: Potential dilution from warrant exercise and increased authorized shares; opportunity to vote on key corporate matters; potential for increased future capital and strategic flexibility.
• Employees: Potential for increased equity awards under the expanded stock incentive plan.
• Management: Continued roles and compensation structure, with potential for equity incentives.
• Creditors: Increased authorized shares and potential capital raises could impact financial leverage and debt covenants.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on August 3, 2026.
• If approved, the amendment to the 2020 Stock Incentive Plan will become effective on the earlier of consummation of a strategic transaction or January 1, 2027.
• If approved, the amendment to the Articles of Incorporation to increase authorized shares will be effected by filing with the Secretary of State of the State of Nevada, at the Board's discretion within one year of stockholder approval.
• If approved, the New Warrants will become exercisable commencing on the Stockholder Approval Date.
• The company will file a Current Report on Form 8-K with the SEC to announce the voting results of the Annual Meeting.

Key Dates

Recommendation

The filing outlines necessary corporate actions for future growth and operational flexibility, including increasing authorized shares and the stock incentive plan. However, the significant potential dilution from the warrant exercise proposal, coupled with past difficulties in securing stockholder approval for similar matters, introduces considerable risk. While the company needs these tools for growth, the immediate impact on existing shareholders warrants a cautious 'hold' recommendation until the outcomes of these proposals and their subsequent impact on share structure are clearer.

Keywords

Theriva Biologics, Annual Meeting, Proxy Statement, Stockholder Vote, Director Election, Auditor Ratification, Stock Incentive Plan, Authorized Shares, Warrant Exercise, Private Placement, NYSE American